Pharma BD Deal Intelligence
Pfizer Inc. / Biocon Limited (biosimilar insulin license)
2010 · Licensing/Option · $350M · Terminated
Announcement Sentiment
40
Skeptical
Pfizer/Biocon global commercialization agreement: $200M upfront + up to $150M development/regulatory milestones + sales-linked payments. Pfizer to commercialize Biocon's biosimilar insulins worldwide.
Key facts
- Announced Oct 18, 2010
- Deal value $350M
- Deal type Licensing/Option
- Therapeutic area Diabetes mellitus
- Indications Diabetes mellitus
- Key assets Biosimilar insulin portfolio (recombinant human insulin, glargine, aspart, lispro)
- Mechanism Biosimilar insulin and insulin analogs
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals